Related Experiment Video

Updated: Aug 14, 2026

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
10:04

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

Amyloidosis: diagnosis and management

Morie A Gertz1, Martha Q Lacy, Angela Dispenzieri

  • 1Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. gertm@mayo.edu

Clinical Lymphoma & Myeloma
|December 16, 2005
PubMed

Insights

Amyloidosis is a rare plasma cell disorder with vague symptoms, making diagnosis challenging. Advances include serum free light chain assays and new therapies like chemotherapy and thalidomide.

Area of Science:

  • Hematology
  • Oncology
  • Nephrology

Background:

  • Amyloidosis is a rare plasma cell disorder with an incidence of 8 in 1,000,000.
  • Symptoms are often vague, including dyspnea, edema, and fatigue, complicating diagnosis.
  • Clinical presentations range from nephrotic syndrome to cardiomyopathy and neuropathy.

Purpose of the Study:

  • To review the diagnostic challenges and recent therapeutic advancements in amyloidosis.
  • To highlight the role of serum immunoglobulin free light chain assays in classification and monitoring.
  • To discuss the significance of cardiac biomarkers and novel treatment strategies.

Main Methods:

  • Review of clinical presentations and diagnostic workup for amyloidosis.
  • Evaluation of the utility of serum immunoglobulin free light chain assays.
  • Assessment of emerging therapies, including high-dose chemotherapy and thalidomide.

Main Results:

  • Serum free light chain assay aids in classifying amyloidosis and monitoring treatment.
  • Cardiac biomarkers are increasingly recognized for outcome assessment.
  • Recent therapies show promise in managing this complex disorder.

Conclusions:

  • Amyloidosis diagnosis requires a high index of suspicion due to nonspecific symptoms.
  • Advancements in diagnostics and therapeutics are improving patient outcomes.
  • Multidisciplinary approaches are crucial for effective amyloidosis management.

More Related Videos

Performing and Processing FNA of Anterior Fat Pad for Amyloid09:41

Performing and Processing FNA of Anterior Fat Pad for Amyloid

Published on: October 30, 2010

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment: